Foresite Capital Management IV, LLC Diversified Active

Name: Foresite Capital Management IV, LLC Q1 2024 13F Filing | 13F Explorer
Creator: Foresite Capital Management IV, LLC
Published: 2024-05-15

Location: West Hollywood, CA

CIK: 0001704132 · Show all filings

Period: Q1 2024 (← Previous) (Next →)

Filing Date: May 15, 2024

Total Value: $198M (100.0% shares, 0.0% debt)

Holdings (5)

PHVS Pharvaris N.V. 47.2%

Value $93.34M Shares 4,038,842 Est. Cost $27.96 Unrealized -5.0%

KURA Kura Oncology, Inc. 19.9%

Value $39.46M Shares 1,849,947 Est. Cost $20.39 Unrealized -4.6%

— Kinnate Biopharma Inc. 13.0%

Value $25.73M Shares 9,671,643 Est. Cost $39.78 Unrealized —

SNDX Syndax Pharmaceuticals, Inc. 10.5%

Value $20.82M Shares 875,000 Est. Cost $22.62 Unrealized -1.4%

— Lyell Immunopharma, Inc. 9.4%

Value $18.56M Shares 8,325,000 Est. Cost $16.24 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
PHVS	Pharvaris N.V.	4,038,842	$93.34M	47.2%	$27.96	-5.0%	COM	N69605108
KURA	Kura Oncology, Inc.	1,849,947	$39.46M	19.9%	$20.39	-4.6%	COM	50127T109
—	Kinnate Biopharma Inc.	9,671,643	$25.73M	13.0%	$39.78	—	COM	49705R105
SNDX	Syndax Pharmaceuticals, Inc.	875,000	$20.82M	10.5%	$22.62	-1.4%	COM	87164F105
—	Lyell Immunopharma, Inc.	8,325,000	$18.56M	9.4%	$16.24	—	COM	55083R104